A new study suggests long-term use of GlaxoSmithKline's diabetes drug Avandia may increase bone loss in diabetes patients. The study, conducted on mice, suggests Avandia -- which earlier was found to suppress bone-building osteoblasts -- also stimulates the action of osteoclasts, cells that naturally degrade bone. "Because Avandia is effective in controlling glucose and restoring the body's sensitivity to insulin, we do not recommend that people stop their treatment," the lead author cautioned.

Full Story:

Related Summaries